Biopharmaceuticals
HIV/AIDS
News Release - October 4, 2019
Johnson & Johnson Commits $500 Million Investment Over Four Years to Help End the Epidemics of HIV and Tuberculosis
Source: Johnson & Johnson
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.